【U.S. Stock Market Movement】Gilead Sciences surged on October 30: Q3 earnings beat expectations, sales guidance raised, HIV drug sales showed strong growth

Gilead Sciences October 30 Rally Analysis

Keywords: Q3 performance beats expectations, raised sales guidance, strong HIV drug growth

1. On October 29, 2026, Gilead announced its Q3 2026 financial results, with adjusted earnings per share of $2.55, above analysts’ expectations of $2.19; revenue reached $8.3 billion, up 13% year-on-year, beating the expected $7.809 billion; core business sales were $8.2 billion, up 16% year-on-year, marking the strongest growth rate in more than a decade; the company raised its 2026 annual product sales guidance from $30.1-30.4 billion to $31-31.3 billion.

2. On October 29, 2026, the company’s HIV drug sales were robust, with HIV revenue of $6.2 billion, up 18% year-on-year; Biktarvy sales were $4.1 billion, up 10% year-on-year, and U.S. treatment market share reached a record high of 53%; PrEP sales nearly doubled, Descovy sales totaled $1 billion, up 49% year-on-year, Yez2go sales reached $305 million, up 31% quarter-on-quarter; Livdelzi sales stood at $203 million, up 93% year-on-year, and Trodelvy sales totaled $506 million, up 42% year-on-year.

3. On October 30, 2026, multiple institutions raised their price targets: Needham raised its target to $200, Citigroup to $188, Leerink Partners to $145, and RBC to $131.

(Disclaimer: This content is generated by AI based on publicly available information and is for reference only. It does not constitute investment advice.)